Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Mozobil

(Plerixafor)

ApprovedSmall molecule

GGenzyme, a Sanofi Company

Plerixafor is used to help mobilize stem cells in the bone marrow into the bloodstream so they can be collected for transplantation in patients with certain blood cancers and other blood disorders.[2] Mozobil is currently approved and in use across 28 indications[4].[1]

Mozobil is one of 417 small molecule programs targeting Multiple Myeloma. It is currently in Approved.

28

Indications

104

Total Trials

17

Active Trials

416

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Multiple MyelomaTerminated

Sickle Cell DiseaseActive, not recruiting

Hodgkins LymphomaApproved

Chronic Liver FailureApproved

NeutropeniaApproved

Kidney DiseaseApproved

Acute Leukemia of Ambiguous LineageApproved

Acute Graft Vs. Host DiseaseApproved

Hematopoietic and Lymphoid Cell NeoplasmApproved

Diabetic FootApproved

Multiple MyelomaPhase 3

Terminated

Sickle Cell DiseasePhase 2

Active, not recruiting

Hodgkins LymphomaApproved

Approved

Chronic Liver FailureApproved

Approved

NeutropeniaApproved

Approved

Kidney DiseaseApproved

Approved

Acute Leukemia of Ambiguous LineageApproved

Approved

Acute Graft Vs. Host DiseaseApproved

Approved

Hematopoietic and Lymphoid Cell NeoplasmApproved

Approved

Diabetic FootApproved

Approved

Showing 10 of 28 indications

Competition

Competitive Landscape

282 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Fludara

Mozobil

GGenzyme, a Sanofi Company

TALVEY

Johnson & Johnson

Keytruda

Biaxin

Opdivo

Bristol-Myers Squibb

Azatiq

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Vepesid

Cytosar

Etentamig

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Diffuse Large B-Cell Lymphoma

NCT02570542

Q1 2027

Phase 1/2Active, not recruiting

Sickle Cell Disease

NCT05357482

PreclinicalActive, not recruiting

Recurrent Grade 1 Follicular Lymphoma

NCT01318317

Q2 2027

Phase 1Recruiting

Stem Cells

NCT06414889

Q3 2027

Phase 1Active, not recruiting

Sickle Cell Disease

NCT03664830

Clinical

Trials by Indication[1]

Multiple Myeloma15 trials

MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma

Completed·—·Phase 2·NCT04552743·25 enrolled

Stem Cell Transplantation for Patients With Multiple Myeloma

Completed·UUniversity of Chicago·Phase 1·NCT01526096·30 enrolled

Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma

Completed·WWeill Medical College of Cornell University·Phase 3·NCT01146834·47 enrolled

Show 12 more trials

Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).

Completed· Sanofi logo

Sanofi·Phase 2·NCT00665314·5 enrolled

TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma

Withdrawn·JJonsson Comprehensive Cancer Center·Phase 1·NCT03506802

Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma

Completed·WWashington University School of Medicine·Phase 2·NCT02098109·100 enrolled

Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide

Terminated·—·Phase 3·NCT01301963·9 enrolled

Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) Patients

Completed·FFondazione EMN Italy Onlus··NCT03406091·300 enrolled

Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma

Completed·—·Phase 1/2·NCT00903968·58 enrolled

Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662).

Completed· Sanofi logo

Sanofi··NCT00741780·164 enrolled

Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma

Completed·—·Phase 1·NCT01074060·18 enrolled

This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.

No longer available· Sanofi logo

Sanofi··NCT00720603

An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells

Completed· Sanofi logo

Sanofi·Phase 2·NCT01753453·23 enrolled

Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant

Completed·MMayo Clinic·Phase 2·NCT00998049·40 enrolled

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06207799·40 enrolled

Sickle Cell Disease9 trials

A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease

Completed·SSangamo Therapeutics·Phase 1/2·NCT03653247·7 enrolled

Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT02193191·25 enrolled

Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) Patients

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 1·NCT03226691·15 enrolled

Show 6 more trials

Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease

Terminated·EEnsoma·Phase 2·NCT05445128·1 enrolled

Gene Editing For Sickle Cell Disease

Recruiting·SSt. Jude Children's Research Hospital·Phase 1·NCT06506461·25 enrolled

Peripheral Blood Stem Cell Collection From Patients With Sickle Cell Disease (SCD) Using Plerixafor

Withdrawn·SSt. Jude Children's Research Hospital·Phase 2·NCT04817345

Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease

Completed·AAlessandra Biffi·Phase 1·NCT02989701·6 enrolled

Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia

Active, not recruiting·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 1/2·NCT05357482·40 enrolled

A Pilot Study To Evaluate The Safety And Feasibility of Hematopoietic Progenitor Cell Mobilization With Plerixafor as Part of a Gene Therapy Strategy in Sickle Cell Disease

Active, not recruiting·CCity of Hope Medical Center·Phase 1·NCT03664830·5 enrolled

Stem Cells5 trials

Assessment of Tolerance of Mobilizing Peripheral Hematopoietic Stem Cells by Plerixafor in Sickle Cell Patients

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 1/2·NCT02212535·3 enrolled

Mobilization by Plerixafor of Haematopoietic Stem Cells in Children

Completed·UUniversity Hospital, Clermont-Ferrand·Phase 2·NCT01225419·5 enrolled

Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium

Recruiting·HHugh Taylor·Phase 1·NCT05343572·90 enrolled

Show 2 more trials

Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06414889·4 enrolled

Plerixafor as a Salvage Regimen to Mobilize Allogeneic Stem Cells in Healthy Volunteers

Completed·TTechnische Universität Dresden·Phase 2·NCT01954914·39 enrolled

Lymphoma5 trials

Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation

Completed· Sanofi logo

Sanofi·Phase 3·NCT01767714·100 enrolled

Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma

Terminated·—·N/A·NCT01408043·25 enrolled

Long-Term Follow-up Study for Non-Hodgkin's Lymphoma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3101 Study (NCT00103610).

Completed· Sanofi logo

Sanofi··NCT00741325·178 enrolled

Show 2 more trials

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

Terminated·—·Phase 2·NCT01746173·5 enrolled

Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT01097057·20 enrolled

Stem Cell4 trials

Mozobil for Autologous Stem Cell Mobilization

Completed·SSheba Medical Center·Phase 2·NCT01164345·20 enrolled

Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil®) in a Population at Risk for Poor Stem Cell Mobilization

Completed·CCancerCare Manitoba·Phase 2·NCT01037517·52 enrolled

Plerixafor for Stem Cell Mobilization in Normal Donors

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01818284·22 enrolled

Show 1 more trial

Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection

Unknown status·—·N/A·NCT01042717·10 enrolled

48 more indications

Acute Myeloid Leukemia4 trials

Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed· Sanofi logo

Sanofi·Phase 1·NCT00990054·36 enrolled

Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)

Completed·WWeill Medical College of Cornell University·Phase 1·NCT01352650·71 enrolled

Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia

Completed·WWashington University School of Medicine·Phase 1/2·NCT00906945·39 enrolled

Show 1 more trial

IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML)

Terminated·WWashington University School of Medicine·Phase 1·NCT01027923·6 enrolled

Fanconi Anemia4 trials

Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and Plerixafor

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 1/2·NCT02678533·4 enrolled

Lentiviral-mediated Gene Therapy of Fanconi Anemia Patients Subtype A

Completed·HHospital Infantil Universitario Niño Jesús, Madrid, Spain·Phase 1/2·NCT03157804·9 enrolled

Clinical Phase II Trial to Evaluate CD34+ Cells Mobilization and Collection in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene. FANCOSTEM-1

Completed·HHospital Universitari Vall d'Hebron Research Institute·Phase 2·NCT02931071·13 enrolled

Show 1 more trial

Gene Therapy for Fanconi Anemia

Terminated·FFred Hutchinson Cancer Center·Phase 1·NCT01331018·3 enrolled

Leukemia3 trials

Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML)

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT01160354·22 enrolled

Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia

Completed·PPETHEMA Foundation·Phase 1/2·NCT01435343·55 enrolled

Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00943943·33 enrolled

Transplantation3 trials

Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation

Terminated· Sanofi logo

Sanofi·Phase 2·NCT00396383·9 enrolled

Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation

Completed· Sanofi logo

Sanofi··NCT01738373·262 enrolled

Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation

Completed·UUniversity of Florida·Phase 2·NCT01339572·72 enrolled

Hematologic Malignancies3 trials

T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT01621477·34 enrolled

Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Terminated·FFred Hutchinson Cancer Center·N/A·NCT01076270·1 enrolled

MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies

Terminated·EEnsoma·Phase 2·NCT04762875·7 enrolled

Donor3 trials

Healthy Donor Study II - Comparing Plerixafor With G-CSF and Plerixafor

Completed·SStephen Couban·Phase 2·NCT01403896·10 enrolled

Donor Enhancement With Plerixafor Post Myeloablative Allogeneic Transplant

Completed·MMitchell Horwitz, MD·Phase 1/2·NCT01280955·41 enrolled

Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors

Completed·WWashington University School of Medicine·Phase 2·NCT01158118·48 enrolled

Glioma2 trials

Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma

Completed·LLawrence Recht·Phase 1/2·NCT01977677·30 enrolled

Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma

Terminated·PPatrick Y. Wen, MD·Phase 1·NCT01339039·26 enrolled

Myelodysplastic Syndrome2 trials

Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS)

Completed·WWashington University School of Medicine·Phase 1·NCT01065129·28 enrolled

A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.

Completed·—·Phase 1/2·NCT01236144·113 enrolled

Safety and Efficacy1 trial

A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor

Completed·CCenter for International Blood and Marrow Transplant Research·Phase 2·NCT01696461·127 enrolled

Chemotherapy1 trial

Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection

Completed·EEmory University·Phase 2·NCT01095757·45 enrolled

Pediatric Cancer1 trial

A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone

Completed· Sanofi logo

Sanofi·Phase 1/2·NCT01288573·46 enrolled

Observational Study1 trial

Prospective Observational Study on Plerixafor After Chemotherapy

Completed·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano··NCT01700608·27 enrolled

Hyperbaric Oxygen Therapy1 trial

Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers

Withdrawn·UUniversity of Maryland, Baltimore·Phase 2·NCT02682953

Conditioning1 trial

Plerixafor/G-CSF as Additional Agents for Conditioning Before HSCT in CGD Patients

Unknown status·FFederal Research Institute of Pediatric Hematology, Oncology and Immunology·Phase 2·NCT03547830·17 enrolled

Acute Leukemia1 trial

Plerixafor Plus Donor Lymphocyte Infusion for Relapsed Acute Leukemia After Allo-HSCT

Unknown status·TThe First Hospital of Jilin University·Phase 2·NCT06141304·28 enrolled

Malignant Glioma1 trial

O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas

Terminated·FFred Hutchinson Cancer Center·Phase 1/2·NCT00669669·12 enrolled

Allogeneic Stem Cell Transplantation1 trial

A Pediatric Study of a Plerixafor Containing Regimen In Second Allogeneic Stem Cell Transplantation

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT01068301·12 enrolled

Efficacy1 trial

Study in Healthy Volunteers, to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (Ronacaleret)

Completed· GSK logo

GSK·Phase 1·NCT01802892·24 enrolled

MPA1 trial

Quantitating the Impact of Plerixafor

Unknown status·EE. Steve Woodle·Phase 1/2·NCT02522572·12 enrolled

Advanced Hematologic Malignancies1 trial

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Recruiting·SStanford University·Phase 1·NCT05088356·60 enrolled

Autologous Hematopoietic Stem Cell Transplantation1 trial

Mozobil for Autologous Hematopoietic Stem Cell Transplantation

Recruiting·TThomas Jefferson University·Phase 2·NCT07188090·100 enrolled

Autologous Stem Cell Transplantation1 trial

Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation

Terminated·TTufts Medical Center·Phase 1·NCT01610999·7 enrolled

Wound Healing1 trial

Plerixafor in Diabetic Wound Healing

Terminated·GGian Paolo Fadini·Phase 2·NCT02790957·25 enrolled

Renal Impairment1 trial

Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100 (Plerixafor) In Subjects With Renal Impairment

Completed· Sanofi logo

Sanofi·Phase 1·NCT00445302·23 enrolled

Oncology Patients1 trial

Stem Cell Harvesting Using GCSF Plus Plerxiafor, in First -Line, for Heavily Pre- Treated Pediatric Oncology Patients.

Unknown status·TTel-Aviv Sourasky Medical Center·Phase 4·NCT02006225·30 enrolled

Plasma Cell Myeloma1 trial

Collection of Transplant Stem Cells for Plasma Cell Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01547806·49 enrolled

Scleroderma1 trial

Scleroderma Treatment With Autologous Transplant (STAT) Study

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT01413100·21 enrolled

Type 1 Diabetes1 trial

Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)

Completed·UUniversity of Alberta·Phase 1/2·NCT03182426·22 enrolled

Chronic Lymphocytic Leukemia1 trial

Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed· Sanofi logo

Sanofi·Phase 1·NCT00694590·24 enrolled

Colorectal Adenocarcinoma1 trial

To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas

Terminated·WWeill Medical College of Cornell University·Phase 1·NCT03277209·2 enrolled

Colorectal Cancer1 trial

To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers

Completed·CCCTU- Cancer Theme·Phase 1·NCT02179970·26 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT02570542·59 enrolled

Glioblastoma1 trial

Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma

Completed·LLawrence D Recht·Phase 2·NCT03746080·21 enrolled

Tics1 trial

Study Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MGTA-145 in Healthy Volunteers as a Single Agent or in Combination With Plerixafor

Completed·EEnsoma·Phase 1·NCT03932864·107 enrolled

Advanced Cancer1 trial

Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer

Terminated·JJonsson Comprehensive Cancer Center·Phase 1·NCT03240861·5 enrolled

Pancreatic Cancer1 trial

Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT04177810·25 enrolled

HIV infection1 trial

HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection

Withdrawn·FFred Hutchinson Cancer Center·Phase 1·NCT02343666

G-CSF1 trial

Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00822770·47 enrolled

WHIM1 trial

Phase 1/2 Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM

Enrolling by invitation·NNational Institute of Allergy and Infectious Diseases (NIAID)·Preclinical·NCT07775313·10 enrolled

HIV1 trial

A Phase I/II Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Transplantation Followed by GVHD Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies in People Living With HIV (PLWH)

Recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT05470491·265 enrolled

Recurrent Grade 1 Follicular Lymphoma1 trial

Phase I/II Study of Cellular Immunotherapy Using Central Memory-Enriched CD8+ T Cells Lentivirally Transduced to Express A CD19-Specific Chimeric Immunoreceptor Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma

Active, not recruiting·CCity of Hope Medical Center·Preclinical·NCT01318317·8 enrolled

Plasma Cell Leukemia1 trial

Quadruplet Induction Followed by Teclistamab Consolidation and Doublet Maintenance in Patients With Primary Plasma Cell Leukemia: The QUANTUM Trial

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT07605416·74 enrolled

Bone Marrow Failure Syndrome1 trial

Stem Cell Mobilization and Apheresis for Life-threatening Blood Disorders

Not yet recruiting·SSt. Jude Children's Research Hospital·Phase 1·NCT07585136·12 enrolled

Idiopathic CD4-Positive1 trial

Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT02015013·40 enrolled

AML, Childhood1 trial

A Phase I/II Pilot Study of Memory-like NK Cells to Consolidate TCRαβ T Cell Depleted Haploidentical Transplant in High-risk AML

Recruiting·WWashington University School of Medicine·Preclinical·NCT06158828·68 enrolled

Chronic Granulomatous Disease (CGD)1 trial

Phase 1/2 Trial of Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-linked Chronic Granulomatous Disease

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Preclinical·NCT06325709·15 enrolled

Myelokathexis1 trial

A Phase III Double-Blind Randomized Crossover Study of Plerixafor Versus G-CSF in the Treatment of Patients With WHIM Syndrome.

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Preclinical·NCT02231879·20 enrolled

Unspecified3 trials

Alteration in Timing of Plerixafor Administration

Completed·EEmory University·Phase 2·NCT01149863·34 enrolled

Feasibility and Efficiency Study of Leukemic Cell Mobilization With Plerixafor Injection

Completed·UUniversity Health Network, Toronto··NCT01141543·12 enrolled

A Phase I Dose Escalation Study of Plerixafor in Healthy Subjects of Japanese Descent

Completed· Sanofi logo

Sanofi·Phase 1·NCT01579149·24 enrolled

Regulatory

FDA Approval Timeline[5]

Dec 15, 2008

MOZOBIL

NDA NDA022311

Sources

References

[1]
ClinicalTrials.gov — 104 trial records for Plerixafor. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Mozobil drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Plerixafor compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Plerixafor. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA022311). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Genzyme, a Sanofi Company company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: C-X-C Chemokine Receptor Type 4 Partial Agonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: GGenzyme, a Sanofi Company

Related News